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Summary. A prospective study of a normal childhood popu- 
lation identified 44 islet cell antibody positive individuals. 
These subjects were typed for HLA DR and DQ alleles and 
investigated for the presence of antibodies to the Mr 64,000 
(64K) islet cell antigen, complement-fixing islet cell anti- 
bodies and radiobinding insulin autoantibodies to determine 
their potency in detecting subjects with impaired Beta-cell 
function. At initial testing 64K antibodies were found in six of 
44 islet cell antibody positive subjects (13.6 %). The same 
sera were also positive for complement-fixing islet cell anti- 
bodies and five of them had insulin autoantibodies. During 
the follow-up at 18 months, islet cell antibodies remained e- 
tectable in 50 % of the subjects tudied. In all six cases who 
were originally positive, 64K antibodies were persistently de-
tectable, whereas complement-fixing slet cell antibodies be- 
came negative in two of six and insulin autoantibodies in one 
of five individuals. HLA DR4 (p < 0.005) and absence of as- 
paric acid (Asp) at position 57 of the HLA DQ 13 chain 
(p < 0.05) were significantly increased in subjects with 64K 
antibodies compared with control subjects. Of 40 individuals 
tested in the intravenous glucose tolerance test, three had a 
first phase insulin response below the first percentile of nor- 
mal control subjects. Two children developed Type i (in- 
sulin-dependent) diabetes mellitus after 18 and 26 months, 
respectively. Each of these subjects was non-Asp homozy- 
gous and had persistent islet cell and 64K antibodies. We con- 
clude that 64K antibodies, complement-fixing slet cell anti- 
bodies and insulin autoantibodies represent sensitive 
serological markers in assessing high risk for a progression to
Type 1 diabetes in islet cell antibody positive non-diabetic in- 
dividuals. 
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Type 1 (insulin-dependent) diabetes mellitus is caused by a 
chronic autoimmune process where pancreatic Beta cells 
are specifically destroyed. In Caucasian diabetic patients 
95 % possess the HLA DR3 and/or DR4 alleles [1]. Sus- 
ceptibility to Type 1 diabetes has also been demonstrated 
in patients with the absence of asparic acid (Asp) at amino 
acid residue 57 of the HLA DQ 13 chain [2]. Several studies 
on first degree relatives have revealed along pre-diabetic 
period in which the appearance ofType i diabetes-specific 
autoantibodies and the loss of the early phase insulin re- 
sponse to intravenous glucose indicate a high risk for the 
precipitation ofthe disease [3-5]. In family studies, persis- 
tent cytoplasmic islet cell antibodies (ICA) at high levels as 
well as the presence of complement-fixing ICA (CF-ICA) 
and radiobinding insulin autoantibodies (CIAA) have 
beencorrelatedwithprogressiontoType i diabetesinnon- 
diabetic individuals [6, 7]. 
The Mr 64,000 (64K) islet cell protein, now recognized 
as glutamate decarboxylase (GAD) [8] is a major target 
antigen in Type i diabetes. Immunoprecipitating anti- 
bodies to this protein have been found in 80 % of newly- 
diagnosed cases, and they have also been detected in the 
pre-diabetic period in first degree relatives of Type 1 
diabetic patients who later developed iabetes [9-11]. 
The present prospective study, started in 1988 and was 
designed to investigate he course of the pre-diabetic peri- 
od in a random childhood population. Separate aspects of 
this study have been published recently [12, 13]. Here we 
addressed the question of whether the detection of anti- 
bodies to the 64K protein or other Type 1 diabetes pecific 
autoantibodies can be correlated with genetic high risk 
markers and impaired Beta-cell function. 
Subjects and methods 
A total of 4208 school children a d adolescents (2292 females, 1916 
males, mean age 13.9 years, range 7-21 years) from the Ulm/Alb- 
Donau County in southern Germany were screened for ICA be- 
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Figol. Fluorogram showing immunoprecipitation f 35S-meth- 
ionine-labelled porcine islet cell proteins by two islet cell antibody 
positive subjects (ID numbers 2, 3; lanes 1 and 2), the corresponding 
sex- and age-matched control subjects (lanes 4 and 5) and by a mono- 
clonal anti-glutamate d carboxylase antibody (lane 3) 
551 
sample was coded and results were interpreted independently by 
two observers. 
CIAA were detected by the competitive radiobinding assay de- 
scribed by Vardi et al. [18]. A total binding insulin level above 
45 nU/ml (mean + 3 SD of 100 control subjects) was regarded as 
positive. In the First Insulin Autoantibody Proficiency Program our 
laboratory obtained values of 100% of sensitivity and consistency, 
92 % for validity and 87 % for specificity (Lab ID number 116). 
The intravenous glucose tolerance test (IVGTY) was performed 
after an overnight fasting period. Glucose (0.5 g/kg body weight) 
was infused within 2rain. Plasma insulin concentrations were 
measured before, and at1, 3, 5, 10, 20 and 30 min after infusion. In- 
sulin was analysed bydouble antibody radioimmuno-technique (In- 
ternational CIS, Gif-sur-Yvette Cedex, France). The sum of the 
1 + 3 rain insulin values after glucose infusion was used as a par- 
ameter of the first phase insulin response. A suppressed peak insulin 
response was defined as a value below the first percentile (48 gU/ml) 
of 216 normal control subjects (92 females, 128 males, mean age 
29.5 years). In ICA positive individuals the IVGTT was repeated at 
3-6 month intervals. 
HLA analysis of our ICA positive individuals and a control 
population has been published recently [12]. HLA DR typing was 
performed by the two colour fluorescence t chnique. The DQ[3 
chain polymorphism atcodon 57 was determined by DNA amplifi- 
cation and analysis with specific oligonucleotide probes. 
tween July 1988 and July 1989. Informed consent was given by 
the parents of the children studied. The study was approved by the 
local ethical committee and the Data Protection Council and was 
performed according to the principles of the Declaration f Hel- 
sinki. 
ICA were determined by the indirect immunofluorescence test 
on unfixed cryostat Sections of blood group 0 human pancreas [14]. 
The tests were performed without knowledge of the origin of the 
sample by two investigators (G. G-F and G.T.). All determinations 
were carried out on the same tissue and the results were expressed 
in Juvenile Diabetes Foundation (JDF) Units according to the 
workshop rotocol for the standardisation f ICA. The detection 
threshold of the assay in our laboratory was 5 JDF Units with 
values of 100 % for validity, consistency, sensitivity and specificity 
(Second Proficiency Program, LAB ID number: 116). CF-ICA 
were measured by anindirect immunofluorescence assay [14], per- 
formed on the same substrate as for ICA determination. Positive 
sera were titrated to end-point. ICA positive individuals were re- 
tested for ICA and CF-ICA 3, 6, 9, 12 and 18 months after the 
initial screening. 
Antibodies to the 64K antigen (64KA) were determined inpar- 
allel with porcine and human islets as antigen using a modification of
the immunoprecipitation method escribed by Christie et al. [15]. 
Due to the shortage of human islets, porcine preparations were used 
for follow-up investigations. Islets were isolated by the method orig- 
inally recorded by Ricordi et al. [16]. The mean purity of the islets 
was 80-90 %. 
Islets were labelled with 3SS-methionine, homogenised in 
20 retool/1 Tris pH 7.4 supplemented with 2 mmol/1 phenylmethyl- 
sulphonyl fluoride, 2 mmol/1 EDTA and 1% Trasylol (Tris-buffer) 
followed by centrifugation at36,000 x g for 30 rain. The pellet was 
resuspended in Tris-buffer containing 150 mmol/1NaC1 followed by 
the addition of 1% Triton x 100 for 2 h to extract the membrane pro- 
teins. After centrifugation at16,000 x g for 30 min the supernatant 
was prc-cleared with a pool of normal human serum (25 ~tl/100 ~tl ly- 
sate, equivalent to 300 islets) and then precipitated with the test 
serum (25 gl/100 gl lysate) for 12 h. The immune complexes were 
bound to protein A Sepharose (Pharmacia, Freiburg, FRG), washed 
five times and eluted with 62 mmol/1Tris HC1 pH 6.8, 2 % SDS, 5 % 
mercaptoethanol. The proteins were separated by SDS-PAGE using 
a 7.5-15 % linear gradient gel according to the method of Laemmli 
[17] and the precipitates were analysed by fluorography. Each 
Statistical analysis 
Results were expressed as mean + SD. Statistical differences be- 
tween groups were assessed using the Wilcoxon test, the chi-square 
test with Yates' correction or Fisher's exact test, where appropriate. 
Results 
Of the 4208 probands 44 (1.05 %) were ICA  positive at 
initial screening (19 females, 25 males, mean age 13.6, 
range 7-19 years). The mean positive ICA  level was 33.4 
(range 5-160) JDF  Units. None had a family history of 
Type i diabetes. 64KA were detected in six of the 44 
(13.6%) ICA  positive individuals but in none of the 
60 ICA  negative sex- and age-matched control subjects 
(Fig. 1). Identical results were obtained whether porcine 
or human islets were used in our assay (data not shown). 
The data of the 64KA and their correlation to CF - ICA  
and C IAA are given in Table 1. The mean ICA  levels of 
the sera containing 64KA and CF- ICA  (55 +27 JDF  
Units) or of sera containing C IAA (64 + 17 JDF  Units) 
were increased as compared to ICA  levels in sera that 
were only ICA  positive (30 + 33 JDF  Units) (p < 0.05, 
C IAA  vs ICA  positive subjects). 
In contrast to 808 control subjects the frequency of 
HLA DR3 and DR4 was significantly increased in ICA  
positive individuals (p < 0.0005) (Table 2). Twenty-nine 
of 31 (93.5 %) ICA  positive subjects had a non-Asp haplo- 
type (p < 0.02) and 20 (64.5 %) were non-Asp homozy-  
gous or non-Asp/blank at position 57 of the HLA DQ 13 
chain (p < 0.005) compared to 71.5 % and 33.4 % in 123 
control subjects, respectively. Five of six (83.3 %) 64KA 
and CF- ICA  positive subjects possessed a DR4 haplotype 
(p < 0.005), two (16.7 %) had HLA DR3 and five of these 
individuals were non-Asp/non-Asp or non-Asp/blank 
(p < 0.05) (Table 1). 
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Table 1. Islet specific autoantibodies, HLA typing and Beta-cell function in individuals with persistently positive cytoplasmic slet cell anti- 
bodies 
ID age HLA ICA CF-ICA 64KA CIAA IVGTT 
no. sex DR DQ (JDF Units) (titre) (nU/ml) 1 + 3 rain insulin 
(~U/ml) 
0mo 12mo 0mo 12mo 0mo 12mo 0mo 12mo 0mo 12mo 
1 14 F 3,4 NA/NA 80 60 1:4 1:4 + + 178 - 77 139 
2 15 M 1,2 NA/NA 60 20 1:2 1:1 + + 101 104 42 < 7 
3 12 M 4,8 NA/NA 80 80 1:2 1:4 + + 49 66 85 44 
4 13 M 3,4 NA/bja~k 10 10 1:2 - + + - - 58 70 
5 11 M 4,11 NA/AA 60 160 1:2 1:2 + + 241 301 205 152 
6 8 F 4,6 NA/NA 40 10 1:1 - + + 115 55 25 36 
7 8 F 1,3 NA/NA 40 5 . . . . . .  121 n.t. 
8 13 M n.t. n.t. 20 40 . . . . . .  127 258 
9 14 M 6,11 A/A 10 40 . . . . . .  207 491 
10 10 F 4,12 NA/NA 160 40 . . . . . .  222 107 
11 14 M 4, bla"k NA/NA 10 5 . . . . . .  472 286 
ICA, islet cell antibodies; CF-ICA, complement fixing ICA; 64KA, 
antibodies tothe 64K protein; CIAA, insulin autoantibodies, values 
above 45 nU/ml are taken as positive; IVGTT, intravenous glucose 
tolerance t st; A, asparic acid; NA, absence ofaspartic acid at posi- 
tion 57 of the DQ [3 chain; Blank, possibility of homozygosity or
presence ofan unidentified allele; F, female; M, male; mo, months of 
follow-up;-, negative; n. t., not tested 
Table 2. Correlation of the islet cell antibody (ICA) status at the follow-up with the HLA DR and DQ gene frequencies in ICA positive non- 
diabetic individuals compared to ICA negative control subjects from the same population 
ICA status HLA phenotype HLA DQ [3 genotype at position 57 
n DR3 DR4 n A/A or A/blank A/NA NA/NA or NA/blank 
control subjects 808 0.189 0.238 123 0.285 0.382 0.333 
ICA positive 36 0.444 a 0.528 b 31 0.065 0.290 0.645 ~ 
persistent ICA 10 0.300 0.700 c 10 0.100 0.100 0.800 df 
fluctuating ICA 12 0.667 b 0.333 10 0.000 0.300 0.700 e 
transient ICA 8 0.500 0.500 8 0.125 0.625 0.250 
Persistent ICA, ICA positivity at each time point; fluctuating ICA, 
change between positive and negative ICA results during follow-up; 
transient ICA, initially positive ICA but persistent ICA negativity at
the follow-up; A, aspartic acid; NA, absence of aspartic acid at posi- 
tion 57 of the DQ 13 chain; blank, possibility of homozygosity or
presence of an unidentified allele; n, number of subjects. 
a p < 0.0005, b p < 0.0002, c p < 0.005, d p < 0.01, ~ p < 0.05, vs con- 
trol subjects; ~p < 0.05, vs transient ICA 
Table 3. Consistency of cytoplasmic islet cell antibodies (ICA), complement-fixing slet cell antibodies (CF-ICA), antibodies to the 64K 
antigen (64KA) and insulin autoantibodies (CIAA) at the 18-month follow-up 
Months of follow up 
3 6 9 12 18 
Number of subjects 40 35 34 34 28 
ICA positive 22 19 14 17 14 
(21 _+ 21) (25 + 31) (23 _+ 18) (29 + 40) (30 _+ 44) 
CF-ICA positive 5 5 4 5 5 
64KA positive 6 n.t. n.t. 6 6 
CIAA positive 5 4 4 4 n.t. 
The ICA levels (mean + SD) are given in parentheses, n. t., not ested 
The data on the course of ICA  and CF- ICA  during 
an 18-months follow-up are given in Table 3. After 
18 months of initial testing 50 % of the originally ICA  
positive individuals had become ICA negative. As shown 
in Table 4 the presence of 64KA, CF - ICA and C IAA was 
positively correlated with persistent ICA. ICA  persis- 
tency was also associated with HLA DR4 and non-Asp 
homozygosity (Table 2). Individuals with persistently 
detectable ICA  had higher mean ICA  levels (52 + 45 JDF  
Units) as compared to those subjects with transient ICA,  
where ICA  were negative at all fol low-up examinations 
(16 + 10 JDF  Units) (p < 0.02). 64KA were persistently 
detectable in all six subjects who were initially positive 
whereas CF - ICA  were only positive in four of the six and 
C IAA in four of the five initially positive cases. The fre- 
quencies of non-Asp/non-Asp  was significantly increased 
in subjects with 64KA, CF - ICA or persistent ICA  com- 
pared to the group with transient ICA  (p < 0.05). 
Of 44 ICA  positive school chi ldren 40 were available 
for IVGTT's .  Al l  of them were clinically healthy, had nor- 
mal fasting blood glucose and a normal  body mass index. 
Two of the 40 had a first phase insulin response less than 
48 gU/ml. Both subjects with persistently ICA  levels 
greater than 40 JDF  Units, were also persistently positive 
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Table 4. Correlation of cytoplasmic islet cell antibody (ICA) persistency with ICA levels, complement fixing ICA (CF-ICA), antibodies to the 
64K antigen (64KA), insulin autoantibodies (CIAA) and Beta-cell function in the intravenous glucose t l rance t st (IVGTT) 
ICA status ICA (JDF Units) CF-ICA 64KA CIAA 
< 20 20-40 > 40 Mean level 
Persistent 3 3 5 52 • 45" 6 6 5 3 
Fluctuating 5 3 4 35 • 32 . . . .  
Transient 6 5 - 16 • 10 . . . .  
IVGTT 
1 + 3 mm 
< 48 gU/ml 
Persistent ICA, ICA positivity at each timepoint; fluctuating ICA, change between positive and negative ICA results during follow-up; tran- 
sient ICA, initially positive ICA but persistent ICA negativity at the follow-up. 
ap < 0.02 vs transient ICA
for 64KA and CIAA and showed a blunted insulin re- 
sponse in the IVGTF over a period of 15-18 months. In 
another subject hat was positive for 64KA and CF-ICA 
the IVGTT decreased below the first percentile after 
6 months. During the follow-up one of these children (ID 
no. 2) with persistent ICA (20-60 JDF Units), 64KA, CF- 
ICA (titre 1/1 to 1/2) and CIAA (83-195 nU/ml) and an- 
other child (ID no. 1) with persistent ICA (40-80 JDF 
Units), 64KA and CF-ICA (titre 1/2 to 1/4) developed 
Type 1 diabetes after 16 and 26 months of observation, re- 
spectively. In the latter case, CIAA had become negative 
17 months before the onset of Type 1 diabetes. 
Discussion 
The determination of antibodies to the 64K protein, 
radiobinding competitive insulin autoantibodies (CIAA) 
and immunogenetic markers have not been included in 
published population studies o far [19-21]. Based on the 
study of a random population aged 7-21 years we show 
that in ICA positive non-diabetic ndividuals antibodies to 
the 64K antigen, CF-ICA and CIAA are closely corre- 
lated with impaired Beta-cell function, the HLA DR4 
phenotype and the absence of Asp at position 57 of the 
HLA DQ ~ chain. 
With our porcine 64K assay 64KA were detected in six 
out of 44 (13.6 % ) ICA positive individuals. In accordance 
with the results in a family study reported by Atkinson et 
al. [10] we also found an association between 64KA and 
high ICA levels as well as with the presence of insulin 
autoantibodies. We w re able here to show a strong corre- 
lation between 64KA and CF-ICA, which are considered 
as reliable serological markers for active Beta-cell de- 
struction and the progression to diabetes in non-diabetic 
first degree relatives of Type i diabetic patients [4, 6]. The 
high risk for Type i diabetes in the subjects with 64KA 
and CF-ICA in their serum is stressed by the fact that 
three of the six cases had a blunted first phase insulin re- 
sponse in the IVGTT and two children developed Type 1 
diabetes during the follow-up. 
In the report by Atkinson et al. [10] 64KA were posi- 
tive in 23 out of 28 (82 %) first degree relatives who later 
developed iabetes. This finding seems to be in sharp con- 
trast to the frequency of 64KA in our study. However, the 
discrepancy in the prevalences of the 64KA can be ex- 
plained by the different composition of the populations 
studied. We have investigated subjects at low risk for 
Type I diabetes and we further selected individuals ac- 
cording to their ICA status. In our study, 64KA were de- 
tected in more than half of the cases with persistently posi- 
tive ICA and in virtually all individuals who showed 
CF-ICA, CIAA or a blunted first phase insulin response 
to intravenous glucose. These data are in agreement with 
a recently published study of Bfirmeier t al. [11], who 
showed that 64KA are excellent markers for a progressive 
loss of Beta-cell function in first degree relatives of Type 1 
diabetic patients. 
About half of the initially ICA positive subjects be- 
came ICA negative after a period of 18 months. These in- 
dividuals may bear no increased risk for Type 1 diabetes 
[4]. Although our laboratory performed very well in the 
ICA workshops, a variation of I to 2 titres must be con- 
sidered due to intra- assay variation. The majority of our 
cases with seroconversion had ICA levels of 5 to 10 JDF 
Units, but some individuals became ICA negative ven 
after ICA levels of 80 JDF Units had been detected. This 
observation has also been made by other investigators and 
indicates the limited predictive value of a single ICA 
determination. In one study of 321 healthy children Lan- 
din-Olsson et al. [22] showed that seven out of nine ICA 
positive non-diabetic ndividuals became ICA negative in 
a follow-up study after more than 2 years without devel- 
oping Type i diabetes. Transient ICA have also been re- 
ported in the Barts' Windsor family study. Here, suscepti- 
bility to Type i diabetes was only assumed when ICA 
positivity had been confirmed on two further occasions 
after an interval of four months [23]. In contrast to the 
high fluctuation rate of ICA, CF-ICA and CIAA re- 
mained positive in most of our cases, whereas 64KA posi- 
tive subjects eem to remain persistently positive in all 
non-diabetic subjects during the follow-up study. 
The importance of 64KA, CF-ICA and CIAA as sero- 
logical high risk markers for Type 1 diabetes is confirmed 
by the genetic analysis of our ICA positive population. 
HLA susceptibility for Type 1 diabetes in Caucasian indi- 
viduals has been described for HLA DR3, DR4 and a non- 
Asp genotype at position 57 of the HLA DQ ~ chain [1, 2]. 
Recently we reported an association f ICA positivity in 
non-diabetic subj ects with HLA DR3 and DR4 and a non- 
Asp haplotype [12]. In this study we showed for the first 
time that in a population of ICA positive individuals there 
is a significant correlation between the appearance of 
64KA, CF-ICA and CIAA with HLA DR4 and the non 
Asp DQ [3 allele. Five of six 64KA and CF-ICA positive 
individuals were non-Asp homozygous and possessed a 
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DR4 phenotype. These frequencies are in agreement with 
data from Type i diabetic patients from the same ethnic 
origin [12], indicating a high risk for the development of 
Type 1 diabetes in these subjects. 
A l though the present study, based on the investigation 
of 4208 children and adolescents, is too small to make final 
conclusions, our prel iminary results indicate that a single 
ICA  determination is not sufficient o assess the risk for 
Type i diabetes. By additionally detecting 64KA, CF- 
ICA  or C IAA in an ICA  positive populat ion it is possible 
to identify subjects at high risk. As 64KA were shown to 
lack f luctuation these antibodies could be valuable sero- 
logical markers for indicating high risk for the develop- 
ment of Type 1 diabetes in a random population, when 
blood is available only on one occasion. 64KA, CF - ICA  
and C IAA seem to be closely correlated with an irre- 
versible active auto immune process culminating in the 
manifestation of diabetes. Our  results suggest that in pre- 
diabetic individuals without a family history of  Type 1 
diabetes the onset of the disease is preceded by immuno-  
logical mechanisms that are identical with those in sub- 
jects with a family history of Type I diabetes. 
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